CO
The startup develops monoclonal antibody treatments utilizing hybridoma technology to induce programmed cell death in cancer cells. This approach enhances treatment options for cancer patients by targeting specific pathways that lead to tumor cell elimination.
Updated 4 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops monoclonal antibody treatments utilizing hybridoma technology to induce programmed cell death in cancer cells. This approach enhances treatment options for cancer patients by targeting specific pathways that lead to tumor cell elimination.